Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus

Abstract

The present invention relates to a cosmetic composition comprising a combination of nerve growth factor (NGF) inhibitors, that is particularly of use in the topical treatment of pruritus, in particular, that observed in the case of psoriasis or of atopic dermatitis, of chronic urticaria and also of senile pruritus. The invention is directed towards a composition comprising an ambora extract and a green tea extract.

Description

1. COMPOSITION COMPRISING AN AMBORA EXTRACT AND A GREEN TEA EXTRACT FOR THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS, CHRONIC URTICARIA, ANTIHISTAMINE-RESISTANT PRURITUS AND SENILE PRURITUS 5 FIELD OF THE INVENTION The present invention relates to a cosmetic composition comprising a combination of nerve growth factor (NGF) inhibitors that is particularly of use in the topical treatment of pruritus, in particular, pruritus resistant to antihistamines, notably that observed in the case of psoriasis or of atopic dermatitis. More precisely, the cosmetic composition comprises an ambora extract and a green tea extract, as Nerve Growth Factor (NGF) inhibitors, a factor involved in pathological manifestations of psoriasis, atopic dermatitis and in pruritus and itching associated with cutaneous hyperinnervation. BACKGROUND OF THE INVENTION Pruritus may be defined as "an unpleasant sensation which causes the need to scratch" (Misery 2014). It occurs in a large number of circumstances, particularly in the case of skin disorders, but also in the case of accumulation of toxins or general disorders such as hematological or endocrine diseases. Generally, pruritus produces persistent and relentless itching, which has a negative impact on the quality of life of patients. Pruritus is a symptom notably found in skin disorders such as psoriasis, atopic dermatitis, or urticaria. Psoriasis is a chronic inflammatory disease characterized by keratinocyte hyperproliferation and reduced apoptosis, leading to increased epidermal renewal. Atopic dermatitis (AD) is a chronic inflammatory itchy dermatitis linked to a hereditary predisposition of the immune system, which is accompanied by anomalies in the skin barrier. Dermal atopy 10 is reflected by a hypersensitivity to environmental allergens, which are normally tolerated in healthy subjects. In the case of psoriasis, pruritus often constitutes the main reason for consultation. Its care is all the more necessary since the scratching fuels inflammation, just like any trauma (Koëbner phenomenon). Moreover, pruritus can cause an aggravation of the condition, mainly in the case of atopic dermatitis. In this condition, the barrier function of the epidermis is reduced and scratching can further compromise this first line of defense of the body, promoting the penetration of allergens and the adhesion or proliferation of pathogenic microorganisms. Pruritus is a typical symptom of urticaria, in particular, chronic urticaria, a condition characterized by the outbreak of erythema or wheals, which may be confined to certain areas, in small patches or merging into large plaques which are mobile and fleeting. There is no current consensus on the treatment of chronic urticaria, which is generally treated with antihistamine medications. Pruritus is often aggravated in elderly subjects; the decrease in the thickness of the skin, dryness, atrophy, decrease in sebaceous and sudoral secretions and the decrease of the hydrolipid film of the surface play a role in exacerbating pruritus in elderly subjects, along with the decrease of all lipids of the superficial layer of the epidermis. It is difficult to characterize or measure pruritus, since, like the phenomenon of pain, it is essentially a sensory phenomenon. Further, the underlying molecular mechanisms are complex and diverse. Briefly, it is considered that pruritus is a sensory response stemming from the stimulation by certain mediators of sensory receptors known as pruriceptors located on nerve fibers, in particular, C-type nerve fibers located at the dermoepidermal junction of the skin (Jacquier 2008). Type A <semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics> nerve fibers may also play a role in pruritus. Conventionally, pruritus is treated with antihistamine medication. An antihistamine is a medicinal product used as competitive antagonist of histamine receptors, the signaling molecule of the immune system, which is considered to be the main mediator of pruritus. Antihistamines are therefore used to reduce or eliminate the effects of this endogenous chemical mediator released, for example, during allergic reactions, or following an insect bite 11 1. or sting. However, antihistamines are often ineffective in treating specific and recurrent forms of pruritus. Notably, in the scope of psoriasis, numerous studies have shown that there is no correlation between the intensity of pruritus and the level of histamine in the plasma of individual sufferers (Wisnicka et al. 2004). In another study, it has been shown that oral antihistamines are effective in treating pruritus in only 20% of subjects studied suffering from psoriasis (Szepietowski et al. 2002): this indicates that other signaling pathways are involved in the induction and establishment of pruritus, notably within the scope of recurrent pruritus. Recent studies have shown that the Nerve Growth Factor (NGF), a protein belonging to the family of neurotrophins, could play a key role as mediator in the phenomenon of recurrent pruritus. It has been shown that NGF causes the expression of substance P and CGRP (Calcitonin Gene-Related Peptide) in sensory neurons. Substance P and CGRP are neuromediators also known to cause pruritus (Jacquier 2008). In particular, substance P, a neuropeptide belonging to the tachykinin family, is a powerful inducer of pruritus mediated by the release of histamine from the dermal mastocytes (Hägermark et al. 1978). It is also known that neuropeptides such as substance P and CGRP stimulate the proliferation of terminal cutaneous nerve fibers, which is reflected by denser cutaneous innervation. This phenomenon has been notably observed in psoriatic lesions, in which NGF is overexpressed. The increase in the density of cutaneous innervation increases the sensitivity of subjects to mediators of pruritus, by increasing the presence of pruritus receptors. This therefore contributes to the onset of permanent itching, which is resistant to antihistamine treatment. Scratching is the instinctive and natural response to pruritus. It temporarily inhibits it, but the scratching then aggravates the itching by damaging the stratum corneum, and a viscous circle of itch-scratch-itch is created. Thus, although the molecular mechanisms involved are currently still poorly understood, NGF is involved in the sensation of pruritus and in the onset of recurrent and to date, incurable pruritus. There is therefore interest in producing compositions comprising NGF inhibitors, which enable pruritus to be limited or even suppressed. Such compositions would be of particular interest in the treatment and prevention of pruritus in general, and would be particularly useful 11 . . . . . . . . . . . . . . . . . . . . in the treatment of antihistamine-resistant pruritus, notably pruritus in which NGF is overexpressed. NGF is found to be overexpressed in the skin in the pathological or physiological processes characterized by cellular hyperproliferation, as is the case notably during inflammation, healing, or in patients suffering from psoriasis or atopic dermatitis. More precisely, NGF is overexpressed in psoriatic lesions, but also in psoriatic keratinocytes. Furthermore, cultured keratinocytes from non-lesional skin of patients suffering from psoriasis produce 10 times more NGF compared with keratinocytes from healthy donors (Truzzi et al. 2011). The level of NGF is also higher in cutaneous lesions of individuals suffering from atopic dermatitis. In a coculture model of porcine neurons from dorsal root ganglia (DRG) and human skin cells, a recent study has shown that atopic human keratinocytes produce high levels of NGF associated with an increase of CGRP and the growth of type C nerve fibers. It has been suggested that the overexpression of NGF leads to an increase in the density of the epidermal nerve fibers in individuals suffering from atopic dermatitis, with an exacerbation of the sensation of pruritus and itching accompanying this disease (Tominaga et al. 2014). Elsewhere, it has been shown that NGF is involved in the proliferation of keratinocytes, as well as in the phenomenon of inflammation, symptoms present notably in psoriatic lesions. This involvement would be both direct and indirect, mediated in part by substance P and CGRP, the expression of which is stimulated by NGF. Indeed, in humans, it has been shown that these neuropeptides play an important role in the proliferative and inflammatory processes of psoriasis. NGF notably binds to the TrkA receptor, with a strong affinity. The TrkA receptor is a tyrosine kinase type receptor. The binding of NGF causes phosphorylation of the receptor and activation of the PI3K (Phosphatidylinositol 3-kinase) and PLC (phospholipase C) pathways. Via the TrkA receptor, the NGF produces a stimulation effect on the proliferation of cultured keratinocytes, in a dose-dependent way. Furthermore, NGF plays a major role in the neurogenic inflammatory processes. NGF causes degranulation of mastocytes, the recruitment of inflammatory cells via the expression of ICAM-1 in dermal microvascular endothelial cells and the activation of T lymphocytes. Further, NGF has a pro-algesic effect, the action of which seems to be mediated by the TRPV1 receptor (Transient Receptor Potential Vanilloid-1) (Nakamura et al. 1999). In effect, the NGF potentializes the activity of TRPV1 by phosphorylation and promotes the insertion of the receptor to the plasma membrane via the activation of TrkA by a mechanism involving PI3K, PKCδ and Src. In other words, the overexpression of NGF contributes to the onset of painful symptoms. A study has shown a positive correlation between levels of expression of TRPV1 in the epidermis and the age of subjects suffering from pruritus, in particular in response to UV (Lee et al. 2012). Senile pruritus is generally persistent and difficult to treat: the reduction of the levels of NGF, coupled with hydration and reconstitution of the hydrolipidic film may therefore provide an effective treatment strategy for senile pruritus. Several studies have shown that serum levels of NGF are also high in subjects suffering from urticaria (Bonini et al. 1996), establishing a link between chronic urticaria and overexpression of NGF. Consequently, compositions comprising NGF inhibitors could turn out to be very useful in the treatment of these diseases, certainly by reducing or suppressing pruritus, but also by limiting the inflammation and hyperkeratinization. Several approaches have been adopted to act on the NGF pathway, notably for the treatment of pruritus, but also diseases such as psoriasis or atopic dermatitis, notably with a strategy of inhibiting the action of NGF on its TrkA receptor. Mention may be made, for example, of documents WO 01 / 85151, WO 2007 / 022999 and WO 2010 / 077680, which disclose synthetic antagonists of the TrkA receptor, blocking its phosphorylase and / or kinase activity. Furthermore, the use of plant extracts for the treatment of psoriasis or atopic dermatitis is known. . For example, document WO 03 / 057133 describes the use of plant extracts such as extracts of Argemone mexicana and extracts of Cuminum cyminum fruits for the pharmaceutical treatment of psoriasis. Documents CN 1328821, WO 2006 / 135785 and KR 20130100544 disclose the use of natural polyphenols from green tea or green tea extract for the preparation of compositions for the treatment of psoriasis. WO 2010 / 37545 discloses the use of an ambora extract for the treatment of several skin disorders, in particular, rosacea. Cosmetic products are also found, such as "Mild UV Sunscreen for sensitive skin SPF40 / PA+++", marketed by the company Dr.C: Labo Online, and which includes among other ingredients an ambora extract and a green tea extract, whose effectiveness in the treatment of pruritus is unknown. The mechanisms brought into play by these compositions are however unknown, and consequently, their suitability in the particular treatment of pruritus associated with psoriasis, atopic dermatitis, chronic urticaria or even in the treatment of senile pruritus are also unknown. There is a need for alternative treatments for skin presenting antihistamine-resistant pruritus, and in which the synthesis of NGF is increased relative to that of healthy skin, such as psoriasis, atopic dermatitis and chronic urticaria. There is also a need for treatments that can address several aspects of these non-compromising diseases, notably antihistamine-resistant pruritus, in particular, pruritus linked to hyperinnervation arising from the overexpression of NGF and senile pruritus. SUMMARY OF THE INVENTION Surprisingly, the Applicant has shown that ambora extracts and green tea extracts and combinations thereof have several effects, in particular, an inhibiting effect on the overexpression of NGF, an inhibiting effect on cutaneous hyperinnervation and an effect on the release of substance P. These effects are particularly pronounced when the ambora 11 extracts and green tea extracts are used in combination. These interesting effects make the extracts and the combinations thereof particularly useful as an antipruritic agent, notably in the scope of antihistamine-resistant pruritus and senile pruritus and as an effective agent to treat psoriasis, atopic dermatitis and chronic urticaria. A first aspect of the present invention relates to a cosmetic composition comprising an ambora extract and a green tea extract. Ambora extracts and processes to obtain them are well known to those skilled in the art. Ambora (Tambourissa trichophylla) is an evergreen tree or shrub endemic to the Madagascan rainforests. Extracts of ambora suitable within the scope of the invention are for example described in document WO 2010 / 037545. In practice, the ambora extract according to the invention represents preferably between 0.00005% and 1% by weight of the composition, advantageously between 0.001% and 0.1%, even more advantageously 0.05%. Preferably, the ambora extract according to the invention is an extract from leaves of the plant. Preferably, the ambora extract according to the invention is rich in polyphenols, advantageously rich in rutin, nicotiflorin, and / or epicatechin and gallic acid polymers. Advantageously, the total polyphenols of the ambora extract are mainly constituted of gallic acid tannins. Preferably, the ambora extract according to the invention contains between 45% and 75% polyphenols, by weight relative to the weight of the extract. An ambora extract suitable for the invention is an extract corresponding to the INCI name Tambourissa trichophylla leaf extract. By way of example, the product marketed by BAYER HEALTHCARE under the name of ROSABORA may be used within the scope of the invention. In practice, the green tea extract represents preferably between 0.00005% and 1% by weight of the composition, advantageously between 0.001% and 0.1%, even more advantageously 0.03%. Green tea extracts are well known to those skilled in the art. Leaves of the tea bush (Camellia sinensis), notably those of green tea, comprise more than 60% polyphenols by weight of dry material. Among the polyphenols from the flavanol class are found more particularly the catechins, such as catechin, epicatechin, epigallocatechin 3-O-gallate (EGCG). Preferably, the green tea extract according to the invention is an extract from leaves of the tea bush. Preferably, the green tea extract within the meaning of the invention contains more than 15% polyphenols of the catechin sub-family by weight relative to the weight of the extract, advantageously between 19% and 25%. Preferably, the green tea extract according to the invention comprises epigallocatechin 3-O-gallate. According to one embodiment, the green tea extract within the meaning of the invention contains at least 13% epigallocatechin 3-O-gallate (EGCG) by weight relative to the weight of the extract. The green tea extract according to the invention is, by way of example, an extract corresponding to the INCI name Camellia sinensis leaf extract. For illustrative purposes, the product marketed by INDENA under the name of Greenselect® may be used within the scope of the invention. The composition of the invention may further comprise other plant extracts or compounds of interest. Preferably and depending on the envisaged application, the composition comprises, besides the ambora extract and the green tea extract, plant extracts or compounds having a beneficial effect on pruritus, on atopic dermatitis or on psoriasis. The Applicant has determined that the combination of green tea extract, ambora extract and β-glycyrrhetinic acid is particularly advantageous within the scope of an antipruritic composition. Indeed, β-glycyrrhetinic acid rapidly combats pruritus immediately caused by the release of 11 9 histamine, while the green tea extract and ambora extract act on antihistamine-resistant pruritus, lastingly soothing the skin. Thus, advantageously, the composition according to the invention comprises <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>- glycyrrhetinic acid. β-glycyrrhetinic acid, or enoxolone, may be extracted from liquorice root (Glycyrrhiza spp.). In practice, <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>-glycyrrhetinic acid may be present in the form of a pure active agent or in the form of a liquorice extract rich in <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>-glycyrrhetinic acid. Preferably, the composition according to the invention comprises purified <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>- glycyrrhetinic acid with a purity at least equal to 90%, 95%, advantageously 98% by weight. By way of example, the product marketed by MARUZEN, INDENA or MAFCO under the INCI name of glycyrrhetinic acid may be used within the scope of the invention. In practice, the β-glycyrrhetinic acid represents preferably between 0.001% and 2% by weight of the composition, advantageously between 0.01% and 1%, even more advantageously 0.5%. The Applicant has further identified other compounds of particular interest, which may advantageously be added to the composition of the invention, for example to improve the properties thereof. Among these compounds, mention may be made of N-palmitoyl- ethanolamide (PEA), vitamin B3 and derivatives thereof, lipids capable of restoring the skin barrier and polyhydroxy compounds. PEA is well known for exerting biological properties in relation to chronic pain and inflammation, and has notably anti-inflammatory, antinociceptive and neuroprotective properties. PEA has been involved in the inhibition of NGF in a visceral hyperalgesic model (Farguhar-Smith et al. 2002). Advantageously, the composition of the invention further contains N-palmitoyl- ethanolamide (PEA). By way of example, cosmetic raw materials having the INCI name: palmitamide MEA may be used within the scope of the invention. 4. and the second second second In practice, N-palmitoyl-ethanolamide represents preferably between 0.1% and 1.0% by weight of the composition, advantageously 0.3%. Vitamin B3 (also known under the name vitamin PP, niacinamide or nicotinamide) stimulates the synthesis of lipids of the stratum corneum, like ceramides. It also causes the synthesis of several structural proteins of the epidermis, such as filaggrin, involucrin and keratin. Vitamin B3 is a hydrating active agent capable of being used to combat atopic states and severe skin dryness (Soma 2005). Numerous scientific studies have shown anti- inflammatory properties of vitamin B3 (Kim et al. 2010). Advantageously, the composition further contains vitamin B3 and / or a derivative thereof. By way of example of vitamin B3 derivatives, mention may be made of tocopheryl nicotinate or methyl nicotinate. In practice, vitamin B3 and / or a derivative thereof represent preferably between 0.001% and 2% by weight of the composition, advantageously 0.1%. Lipids such as natural constituents of the hydrolipid film, like cholesterol, cutaneous triglycerides, cutaneous free fatty acids and ceramides, enable the skin barrier to be restored. The restoring of a normal hydrolipid film reduces evaporation of cutaneous water, which contributes to combating pre-atopic xerosis. Advantageously, the cosmetic composition further comprises lipids capable of restoring the skin barrier, preferably natural constituents of the hydrolipid film, advantageously selected from the group consisting of cholesterol, squalane, cutaneous triglycerides, cutaneous free fatty acids and ceramides. In one advantageous embodiment, the lipid capable of restoring the skin barrier is squalane. 11 Squalane, within the meaning of the invention, is advantageously of plant origin. By way of example, the raw material PHYTOSQUALAN® marketed by the company SOPHIM may be used within the scope of the invention. In practice, lipids capable of restoring the cutaneous barrier represent preferably between 0.1% and 5% by weight of the composition, advantageously between 1% and 3%. Polyhydroxy compounds contribute to reducing the adhesion of pathogenic bacteria, such as S. aureus, on human skin and nasal mucosa. Mannitol, in particular, has an anti-free radical activity. Advantageously, the cosmetic composition further comprises at least one polyhydroxy compound, preferably selected from the group consisting of rhamnose, xylitol and mannitol. In a particular embodiment of the invention, the cosmetic composition comprises a mixture of rhamnose, xylitol and mannitol. In this particular embodiment, rhamnose represents advantageously between 0.01% and 1% by weight of the composition, xylitol advantageously represents between 0.05% and 2% by weight of the composition and mannitol represents advantageously between 0.005% and 1% by weight of the composition. In a preferred way, the composition according to the invention is presented in a form suitable for topical cutaneous administration; cream, emulsion, O / W or W / O, solution, suspension, gel, milk, lotion, micellar water. Consequently, the present composition may contain any additive or excipient suitable for the formulation and application of said composition, such as for example suspension agents, emulsifiers, anionic, cationic or non-ionic or amphoteric polymers, proteins, vitamins, surfactants, mineral or vegetable oils, antioxidants, waxes, gums, resins, thickening agents, acidifying or alkalinizing agents, pH stabilizers, anti-UV agents, sun filters and screens, preservatives, perfumes, dyes, conventional cosmetic and dermatological adjuvants. Among the known surfactants, non-ionic surfactants are of particular interest. The use of non-ionic surfactants makes it possible to reduce the adhesion and proliferation of 50 Staphyolococcus aureus and opportunistic molds on the skin or nasal mucosa. The addition of these surfactants to the composition is particularly advantageous within the scope of a composition for treating atopic dermatitis, which is characterized by the proliferation of a pathogenic flora. Advantageously, the composition according to the invention comprises at least one non-ionic surfactant, preferably selected from the group consisting of sucrose esters, sorbitan esters and mixtures thereof. Sucrose esters and sorbitan esters suitable for this use are, for example, those described in patent application WO2014 / 023895A1. By way of example, some sucrose esters appropriate within the scope of the invention are notably sucrose stearate, sucrose palmitate, sucrose laurate. Preferably, the sucrose ester is sucrose stearate. Sucrose stearate is a mixture of stearic acid and sucrose esters. Advantageously, the sucrose stearate has an HLB (Hydrophobic- lipophilic balance) of at least 15, preferably 16. Preferably, the sucrose stearate has between 65% and 80% stearic acid by weight relative to the weight of the sucrose stearate, advantageously 70%. Preferably, the sucrose stearate comprises sucrose monoester, at a content of 70% to 80% by weight relative to the total weight of sucrose esters in the surfactant, advantageously 75%. By way of example, the raw material SURFHOPE C1816 marketed by the company MITSUBISHI-KAGAKU FOODS CORPORATION may be used within the scope of the invention. By way of example, some suitable sorbitan esters within the scope of the invention are notably polysorbate 20, polysorbate 60, polysorbate 80. Preferably, the sorbitan ester is polysorbate 20. By way of example, the raw material MONTANOX 20 DF marketed by the company SEPPIC may be used within the scope of the invention. Å, Preferably, the sucrose ester and / or the sorbitan ester represent between 0.01% and 5% by weight of the composition, advantageously between 0.05% and 1%. It is particularly advantageous to formulate the composition of the invention such that it is sprayable. This may be achieved for example by the formulation of specific emulsions comprising particular combinations of excipients. Thus, preferably, the composition of the invention is capable of being sprayed. Thus, preferably, the composition of the invention is an emulsion and further comprises at least one combination of excipients selected from the group consisting of: polar and / or nonpolar oils, and gellan gum, said oils and said gum being emulsified, preferably emulsified by a sucrose ester; - polar and / or nonpolar oils, and gellan gum, said oils and said gum being emulsified, preferably emulsified by an acyl glutamate; polar and / or nonpolar oils, and an acrylate polymer, said oils and said polymer being emulsified, preferably emulsified by an alkyl polyglucoside; - polar oils and / or nonpolar oils, microcrystalline cellulose and an acrylate polymer, said oils and said gum being emulsified, preferably emulsified by a sucrose ester. The composition of the invention is particularly useful in the treatment of dermatological disorders causing pruritus. Thus, the invention targets a composition comprising an ambora extract and a green tea extract, preferably for use as a medicinal product, preferably for use in the treatment of dermatological disorders causing pruritus, preferably selected from psoriasis, atopic dermatitis, chronic urticaria and in the treatment of antihistamine-resistant pruritus or senile pruritus. Advantageously, this use is to prevent recurrences of psoriasis, preferably in subjects having previously followed a curative treatment using corticoids. The composition according to the invention is also suitable for any conventional cosmetic use. Another aspect of the invention relates to a cosmetic treatment and / or cleansing treatment process for psoriatic or atopic skin or skin subject to pruritus consisting of applying on the skin or the scalp a composition comprising an ambora extract and a green tea extract, preferably the composition of the invention. Other aims and advantageous aspects of the invention will become apparent upon reading the examples which follow, given by way of information and in no way limiting, with the support of the appended figures. 10 BRIEF DESCRIPTION OF THE FIGURES Figure 1 illustrates the percentage inhibition of NGF as a function of different concentrations (expressed as percentage by weight relative to the final volume of the culture medium) of ambora extract (A) or green tea extract (B) or N-palmitoyl-ethanolamide (C). Figure 2 illustrates the effects of the combination of an ambora extract and a green tea extract on the sensory neuron neurite extensions after treatment by NGF. The photographs correspond to microscope images taken of keratinocytes cultivated under the conditions described in example 2 in which the nucleii have been marked with DAPI and the beta-tubulin is marked by immunocytochemistry. The marking of beta-tubulin makes it possible to observe the neurites, and to measure their length. Figure 3 illustrates the average PASI Score of the relapses observed in the clinical trial in subjects treated with a composition according to the invention and in subjects treated with the placebo. Figure 4 illustrates the evolution of the pruritus score observed in the clinical trial in subjects treated with a composition according to the invention and in subjects treated with the placebo. Figure 5 illustrates the impact on the quality of life and the pruritus observed in the clinical trial in subjects treated with a composition according to the invention and in subjects treated with the placebo. ż. . . . Figure 6 illustrates the efficacy of a composition according to the invention on the presence of redness and skin flakes and on the thickness of the skin in treated subjects. Figure 7 illustrates the efficacy of the placebo on the presence of redness and skin flakes and on the thickness of the skin in treated subjects. Figure 8 illustrates the average ratings of the 5D-pruritus test criteria at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from psoriasis. Figure 9 illustrates the average ratings of the clinical signs observed at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from psoriasis. Figure 10 illustrates the average ratings of the 5D-pruritus test criteria at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from chronic urticaria. Figure 11 illustrates the average ratings of the clinical signs observed at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from chronic urticaria. Figure 12 illustrates the average ratings of the 5D-pruritus test criteria at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from senile pruritus. Figure 13 illustrates the average ratings of the clinical signs observed at the first visit (first column) and after 21 days of treatment with the product of the invention (second column), in subjects suffering from senile pruritus. 4 ! Example 1 / Effect of ambora extract, green tea extract and N-palmitoyl-ethanolamide (PEA) compound on the inhibition of expression of nerve growth factor (NGF). We have determined in a quantitative manner the effect of the ambora extract, the green tea extract and the N-palmitoyl-ethanolamide (PEA) on the expression of NGF according to the following method. 10 1.1. Method This method comprises the following steps: - HaCaT keratinocytes were seeded at a density of 2.5.104 in 150 μl DMEM culture medium containing 10% fetal bovine serum - HaCaT keratinocytes were incubated with different concentrations of the compounds to be tested, or in the absence of compound to be tested (positive control of NGF expression) for 1 hour. A mixture of inducers of NGF expression was added to the cell culture medium. This mixture comprised a pro-inflammatory cytokine (TNF<semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>), and 3 growth factors (EGF, IGF-1 and TGF-<semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>). The concentration of each of the inducers was 10 ng.ml-1 in the culture medium. - The cell cultures were incubated in the presence of the mixture for 48 hours; _ the supernatant from the cultures was collected; ..... the NGF concentration was measured in the culture supernatants by ELISA; _ this concentration was compared to a control concentration, obtained from the culture not having received any compound likely to decrease the NGF expression (absence of compound to be tested). For statistical analysis, results from 1 to 6 independent experiments were taken into account, each carried out with three identical samples of each tested condition. The quantitative analyses are expressed in the form of an average <semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics> standard deviation. Statistical significance was determined by a Student test. A lower NGF concentration in the culture supernatant having received the compound likely to decrease the NGF expression compared to the control concentration indicates that the said compound is capable of decreasing NGF expression. The differences are considered to be statistically significant from p<0.05. (NS: p>0.05; * : p<0.05; ** : p<0.01; *** : p<0.001). 5 1.2. Results The results of the tests above are shown in Figures 1A, 1B and 1C. The results show that the ambora extract (Figure 1A) and green tea extract (1B) have an inhibiting effect on the expression of nerve growth factor (NGF), which increases with the dose of extract used. At the concentration of 0.005%, an inhibition of more than 95% is obtained with these two extracts. PEA also has an inhibiting effect on the synthesis of NGF (Figure 1C). This effect increases with the dose of PEA used. Example 2 / Effect of mixtures of plant extracts alone and in combination with PEA on the inhibition of neurite growth (density and length of fibers) caused by NGF Pruritus, notably that observed in the case of psoriasis or atopic dermatitis, is typically associated with cutaneous hyperinnervation correlated to an overexpression of nerve growth factor (NGF) in injured tissues. The effects of the extracts and compounds of interest on the growth of neurites was evaluated on sensory neuron cultures after activation by NGF. The ability of the mixtures tested to inhibit the growth of neurites demonstrates the efficacy of these mixtures in inhibiting the expression of NGF and validates their therapeutic interest in the treatment of the abovementioned diseases. 2.1. Method 2.1.1 Culture of sensory neurons Sensory neurons were from rat dorsal root ganglions of 15 days. The isolated dorsal root ganglions were placed in cold Leibovitz medium containing 2% 10,000 U / mL penicillin and 10 mg / mL Streptomycin and 1% BSA. The ganglions were dissociated by trypsinization for 20 minutes at 37°C. The reaction was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM) containing DNAse I grade II (0.1 mg / mL) and 10% fetal bovine serum. The cells were mechanically dissociated by 3 passes in a 10 mL pipette, then centrifuged at 515 g for 10 minutes at 4°C. The supernatant was removed and the lower part (comprising the cells) was taken up into a solution in an enriched DMEM F-12 medium (containing N2 supplement, L-glutamine, 2% PS and 10 ng / mL Neurotrophin 3 (NT3)). The viability of the cells was established by trypan blue cell count. The cells were then seeded in 96-well culture plates treated with poly L-lysine at 20,000 cells per well. They were cultivated in the abovementioned enriched DMEM F-12 medium in an oven at a temperature of 37°C and under controlled atmosphere (5% CO2). _ For the cytotoxicity tests: Immediately after seeding, the compounds to be tested were placed in contact with the neurons in a final volume of 190 µL of the abovementioned enriched DMEM F-12 medium for one hour. 10 μL of a solution of 100 ng / mL of NGF was then added to each culture well, that is to say a final concentration of 5 ng / mL in the culture medium. For each condition, 3 samples were prepared (3 culture wells). ___ For the evaluation of the efficacy of the compounds: Immediately after seeding, the compounds to be tested were placed in contact with the neurons in a final volume of 190 µL of the abovementioned enriched DMEM F-12 medium for one hour. 10 µL of a solution of 100 ng / mL of NGF was then added to each culture well, that 11 is to say a final concentration of 5 ng / mL. For each condition, 5 samples were prepared (5 culture wells). The cells were cultivated for 5 days. After 2 and 4 days of incubation, half the volume of culture medium was sampled and replaced by fresh medium, namely enriched DMEM F-12 containing the compounds to be tested and NGF at 5 ng / mL. 2.1.2 Analysis of the neurons after 5 days of incubation in the presence of the compounds The following various parameters were analyzed: Sensory neuron cell body count, Measurement of the length of the neurite extensions, _ Calculation of the neurite length / cell body count ratio. Sample preparation The culture medium was removed and the cells were washed twice with PBS. The cells were fixed with an ethanol-acetic acid 95 / 5 solution for 5 minutes at -20°C then permeabilized. The cells were incubated in a solution of PBS containing 0.1% of saponin and 1% fetal bovine serum (FBS) for 15 minutes at ambient temperature. This step allows the sites to be saturated in a non-specific manner. The cells were then incubated for 2 hours with mouse monoclonal antibody anti-β-tubulin at a dilution of 1 / 400 in PBS containing 1% FBS and 0.1% saponin. This antibody marks the sensory neurons and their extensions. This antibody is revealed by Alexa Fluor 488 goat anti-mouse antibody for 1 hour. The cell nucleii are revealed by a fluorescent marker (Hoechst solution). 10 photographs of each culture well were taken with automatic microscope (In Cell 2000; GE Healthcare) at x20 magnification. The cell body count of the sensory neurons and the measurement of the length of the neurite extensions were determined using Analyzer software from GE Healthcare. The cell body count is expressed as average number per well. The average length of extensions per well was then normalized by the average number of cell bodies in the same well. The data obtained on the length of the neurites was normalized relative to the culture condition in the presence of NGF (without i. Programme and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s inhibiting compounds), which constitutes arbitrarily 100% of the length of the neurites. The calculation of the length of neurites / cell body count ratio is carried out from this data. 2.2. Results The effects of the compounds were thus evaluated on the neurite length / cell body ratio. The results of the effects of the compounds are shown in the table below. An illustration of these effects is shown in Figure 2. [Image disponible dans le document PDF, Image available in the PDF document] The results obtained show that NGF at 5 ng / ml significantly increases the length of the neurites relative to the same cells cultivated without NGF. An increase of 40% is observed in the presence of NGF, in comparison with cells cultivated without NGF. These results validate the model used. The compounds tested do not significantly modify the number of cell bodies, which confirms that they are non-toxic. The ambora extract inhibits the neurite length / cell body ratio by 5% to 13.5% depending on the concentration, in comparison with the control (presence of NGF, absence of inhibiting compounds). The green tea extract at a concentration of 0.00001% has a strong inhibiting effect with a reduction of 60.5% of neuritic extensions, in comparison with the control (presence of NGF, absence of inhibiting compounds). The combinations of ambora extract and green tea extract very strongly inhibit the length of the neurites, in comparison į. with the control (presence of NGF, absence of inhibiting compounds). Surprisingly, synergistic effects are observed for 4 of the 5 combinations tested. The addition of PEA at 0.000001% to this combination of 2 plant extracts makes it possible to increase the efficacy of the inhibition, in a synergistic manner. Example 3 / Effect of mixtures of plant extracts on the inhibition of the expression of substance P in sensory neurons NGF induces the expression of substance P, a powerful inducer of pruritus mediated by the release of histamine from dermal mastocytes. The ability of the mixtures tested to inhibit the expression of substance P demonstrates the efficacy of these mixtures in inhibiting the expression of NGF and validates their therapeutic interest in the treatment of the abovementioned diseases. 15 3.1. Method The cells were cultured as previously described. The cultures used for immunomarking described in paragraph 1.1.1 were washed once with PBS containing 0.1% saponin and 1% fetal bovine serum (FBS). The cells were then incubated for 2 hours with rabbit polycolonal antibody anti-substance P at a dilution of 1 / 100 in PBS containing 1% FBS and 0.1% saponin. This antibody marks substance P neurons positive. This antibody is revealed by an Alexa Fluor 568 goat anti-rabbit antibody for 1 hour. 10 photographs of each culture well were taken with automatic microscope (In Cell 2000; GE Healthcare) at x20 magnification. The cell body count of substance P positive sensory neurons was performed using Analyzer software from GE Healthcare. 3.2 Results The results obtained are provided in the table below. 1. 22 [Image disponible dans le document PDF, Image available in the PDF document] The results obtained show that the cultures incubated with the ambora extract, green tea extract and PEA, as well as mixtures thereof, have a percentage of substance P positive neurons of between 94 and 81%, in comparison with the control (presence of NGF, absence of inhibiting compounds, corresponding to 100% SP positive neurons). Consequently, these extracts inhibit the number of substance P positive neurons by 6 to 19%, in comparison with the control (presence of NGF, absence of inhibiting compounds). The results obtained show that the combination of ambora extracts and green tea extracts inhibits significantly and in a synergistic way the number of SP positive neurons in 3 of the 5 combinations, in comparison with the control (presence of NGF, absence of inhibiting compounds). The mixtures comprising an ambora extract, green tea extract and PEA significantly 15 inhibit the number of SP positive neurons, regardless of the respective concentrations of the extracts tested. . . ì . . . . . , Example 4 / cream - O / W emulsion . [Image disponible dans le document PDF, Image available in the PDF document] · . 1. . . The percentages shown correspond to the weight of the product indicated relative to the total weight of the composition. Example 5 / cleansing gel 5 The percentages shown correspond to the weight of product indicated relative to the total weight of the composition. [Image disponible dans le document PDF, Image available in the PDF document] . 10 Example 6 - anti-itching spray The percentages shown correspond to the weight of product indicated relative to the total weight of the composition. į. . . . * [Image disponible dans le document PDF, Image available in the PDF document] 4 Example 7 / Clinical study: comparison of the efficacy of the composition of the invention in the treatment of psoriasis, in particular on the severity of relapses of psoriasis, in comparison with a placebo formula. The effect of the composition of the invention in the treatment of psoriasis, in particular on the severity of relapses of psoriasis, was tested during the clinical trial described below. The product corresponding to the formulation of example 4 was clinically tested on subjects suffering from mild to moderate plaque psoriasis, through a placebo-controlled double-blind randomized comparative monocenter study on two parallel groups. 1! 1, .... . . . The placebo had the following formulation: Placebo formulation [Image disponible dans le document PDF, Image available in the PDF document] 7.1 Selection of study subjects. Inclusion criteria Healthy subject (apart from psoriasis) - Subject having given free, informed and express consent - Cooperating subject, informed about the necessity and duration of the controls, allowing full compliance with the protocol implemented by the clinical study center Gender: male or female - Age: over 18 years - Subject having mild to moderate plaque psoriasis at D-X (PASI score <semantics>≤<annotation encoding="application / x-tex">\leq< / annotation>< / semantics> 15) - At D-X: the subject has an outbreak of psoriasis on the day of the visit and has a prescription for dermocorticoids (to be combined with salicylic acid or urea) in order to treat the psoriasis plaques - At D0: the subject has an improvement in their PASI score by <semantics>≥75%<annotation encoding="application / x-tex">\geq 75\%< / annotation>< / semantics> relative to D- X # i 1. - At D0, each score for the intensity of erythema, induration and flaking should be <semantics>≤1<annotation encoding="application / x-tex">\leq 1< / annotation>< / semantics> at the selected area. Exclusion criteria - Pregnant or breast-feeding women, or those planning to become pregnant during the study - Presence of a skin disorder other than psoriasis on the studied areas (according to the assessment by the investigator) - History of erythrodermic psoriasis, pustule psoriasis or severe psoriasis having required hospitalization Forms other than plaque psoriasis Severe psoriasis requiring systemic treatment Subject resistant to localized treatments - Subject presenting clinical signs of infection at the test areas - Taken a topical or systemic treatment during the weeks before likely to falsify the evaluation of skin tolerance of the studied product (according to assessment by the investigator) Subject taking background treatment for psoriasis - Excessive exposure to sun, UV rays or phototherapy during the month preceding and during the study - Subjects having ceased their dermocorticoid treatment more than 3 days before the inclusion visit (D0) - Subjects taking a systemic treatment with immunosuppressants, retinoids or antibiotics in the 14 days prior to the start of the study - Serious illness requiring regular systemic medication (e.g. insulin-dependent diabetes, cancer) or conditions preventing participation or likely to influence the reaction to the test or its evaluation Documented allergies to components of the studied products _ Subject participating in another clinical trial during the study Subject considered by the investigator as to be unlikely to adhere to the protocol. i. 7.2 Conducting the study After treatment with dermocorticoids (from D-X to D0) until the improvement of the psoriasis, the subjects used either the composition of the invention (formulation from example 4), or a placebo. The products (composition according to the invention vs placebo) were applied twice per day for three months, to the body (with the exception of the head), to clean and dry skin, under normal conditions of use. 7.2.1. Evaluation of the severity of the relapses The relapses were documented. The severity of the relapse was evaluated using the PASI score. A relapse is defined by an increase of the PASI (Psoriasis Area Severity Index) score of 50% between D-X and D-0. The PASI score is a well-established method of evaluating the severity of psoriasis, and does not require a more specific description. The PASI score is typically between 0 and 72. Within the scope of the study, however, where the subjects have not applied treatment to the head, the PASI score is between 0 and 64.8. By way of information, the criteria taken into account in the establishment of this score are shown in the table below. 20 PASI SCORE [Image disponible dans le document PDF, Image available in the PDF document] PASI SCORE (excluding head) = <semantics>Tr+MS+MI<annotation encoding="application / x-tex">Tr + MS + MI< / annotation>< / semantics> { | 1 . . . . Where: LESION SCORE [Image disponible dans le document PDF, Image available in the PDF document] SURFACE SCORE: [Image disponible dans le document PDF, Image available in the PDF document] 7.2.2. Evaluation of pruritus The subjects evaluated the average pruritus over their entire body at D-X, D0, D28, D56 and D84, using a scale from 0 to 10 (0: no pruritus and 10: very intense pruritus). 7.2.3. Impact on quality of life At D-X, D0, D28, D56 and D84, the subjects completed a questionnaire on the quality of life reported and described in various publications on psoriasis (PDI: Psoriasis Disability Index – University of Cardiff). The 15 questions relate to daily activities, occupational or school activities (if appropriate), personal relationships, leisure activities and treatment. The maximum score of the PDI is 45 and corresponds to a maximum impact of the disease on the quality of life. 7.2.4. Subjective evaluation questionnaire The subjects completed a subjective evaluation questionnaire at D28, D56 and D84 in 25 order evaluate subjectively (on a scale of 0 to 5) the efficacy of the products on their redness, skin flakes and thickness of their plaques. ∦ I t. 7.2.5. Evaluation of local tolerance Local tolerance of the product was determined at D28, D56 and D84 using the following 5-point scale: very poor, poor, moderate, good, very good. 7.2.6. Observance The investigator asked the subject how often the product was applied and for how many days. 7.2.7. Cosmetic qualities The investigator asked the subjects about the cosmetic qualities of the studied product (on a scale of 0 to 10): appearance, texture, color, smell, ease of application, penetration into 15 the skin, speed of penetration. 7.3 Results 7.3.1. Description of the study population 84 subjects were included in the study. Of this total, 11 did not complete the term of the study: 9 withdrew their consent, one person became pregnant and another individual experienced a serious adverse event (exacerbation of depressive disorders). According to the protocol, the duration of the treatment with corticoids had to be between 4 and 6 weeks. 34 subjects received a shorter treatment, but their participation in the analysis was maintained as the improvement in their PASI score during inclusion met the abovementioned criteria. The treatment extended over a period of 6 days to 6 weeks. Furthermore, the subjects were included on D0 on condition that their PASI score saw an improvement of 75%. One of the subjects only presented an increase of 72% but was included in the analysis, since this deviation was considered to be minor. We also maintained 11 subjects for whom the time between 2 visits was increased by <semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics> 7 days and 14 subjects with minor deviations regarding observance. 37 subjects, aged 43 years on average, were analyzed in the studied product group, and 36 subjects, aged 48 years on average, were analyzed in the placebo group. The subjects for the most part presented phototype II (75.7% in the studied Ţί product group and 80.6% in the placebo group) and had dry skin (97.3% in the studied product group and 100% in the placebo group). During the selection visit, the average PASI score was 3.9 in the studied product group and 4.4 in the placebo group. During the study inclusion visit, after corticoid therapy, this score fell by 84.6% (PASI score: 0.6) and by 81.8% (PASI score: 5 0.8), in the studied product group and the placebo group, respectively. Description of the studied population. [Image disponible dans le document PDF, Image available in the PDF document] The two groups are comparable from the point of view of their general characteristics (age, gender, skin type, phototype) and the severity of their psoriasis during the selection visit (D-X) and their inclusion in the study (D0). 7.3.2 Severity of relapses 15 At D-X (before the treatment with dermocorticoids), the severity of the relapses was not statistically different between the 2 groups (3.9 for the studied product group and 4.4 for the placebo group). From D0 to D84, the average PASI evaluated during the relapses was significantly lower in the studied product group relative to the group using the placebo (<semantics>p=0.0146<annotation encoding="application / x-tex">p = 0.0146< / annotation>< / semantics> - Mann- Whitney test), corresponding to less severe relapses with the studied product. The use of the studied product makes it possible to reduce the severity of the relapses by 47% relative to the placebo (table below and Figure 3). Average PASI score of the relapses. [Image disponible dans le document PDF, Image available in the PDF document] 7.3.3. Efficacy on pruritus From 28 to 84 days after the end of the basic treatment, the intensity of the pruritus decreases, albeit in a non-significant manner. Between D28 and D84, the reduction in the intensity of pruritus tends to be more significant with the composition according to the invention (-34.0%) than with the placebo (-2.8%) (Figure 4). 7.3.4. Quality of life questionnaire (PDI) After 28, 56 or 84 days of use, the PDI score recorded a significant drop for the two products (p < 0.005 – unpaired t test or Wilcoxon signed-rank test) relative to the inclusion visit (improvement in the quality of life). This improvement remained quite stable after 56 and 84 days of use. Between the inclusion visit and 84 days, the PDI score had decreased more with the studied product than with the placebo: decrease of 47.1% with the composition according to the invention and 38.2% with the placebo (Figure 5). 7.3.5. Subjective efficacy The subjects noticed a statistically significant decrease (<semantics>p<0.05<annotation encoding="application / x-tex">p < 0.05< / annotation>< / semantics> - Wilcoxon signed-rank test) in redness, skin flakes and thickness of their psoriasis plaques between D28 and D84 with the studied product (Figure 6). No significant variation was observed with the placebo (Figure 7). 1 4.4 7.3.6. Local tolerance 97.3% of subjects presented good or very good tolerance to the studied product. One of the subjects felt slight tightness over the entire body from D0 to D28. The investigator considered the causality of this intolerance to the product possible. This intolerance did not lead to the stoppage of applications of the product. 100% of subjects presented good or very good tolerance to the placebo. 7.3.7. Cosmetic qualities of the product The cosmetic qualities of the studied product, evaluated on a scale of 0 to 10 by the subjects, were judged good to excellent. 7.4 Conclusions This clinical study was carried out on 84 subjects presenting mild to moderate plaque psoriasis, for 3 months. At the end of treatment by dermocorticoids having led to an improvement of the psoriasis, the studied product or the placebo were applied over the entire body (with the exception of the head) twice per day. 37 subjects (aged 43 years on average) were analyzed in the studied product group against 36 subjects (aged 48 years on average) in the placebo group. At the end of treatment by dermocorticoids and after 3 months of study, the studied product is better than the placebo, after 3 months of study, at: - significantly reducing the severity of relapses: the average PASI score observed during relapses was much lower with the studied product than with the placebo (2.3 against 4.3), corresponding to less severe relapses with the studied product; - improving the clinical signs of psoriasis: significant reduction of erythema, skin flakes and their thickness, stabilization of pruritus; - improving the quality of life: reduction of the impact of psoriasis on the quality of life of 47.1% with the studied product compared with 38.1% with the placebo. The studied product was well-tolerated (97.3% good or very good tolerance). į. The cosmetic qualities of the studied product were judged to be good to excellent, thus enabling good observance. In conclusion, the studied product enables the clinical signs of controlled psoriasis to be maintained and may limit the severity of relapses. Example 8 / Clinical study of the efficacy of the composition of the invention in the treatment of psoriasis The effect of the composition of the invention in the treatment of psoriasis was tested during the clinical trial described below. The product corresponding to the formulation of example 6 was clinically tested in adult subjects presenting mild to moderate psoriasis. This involved the subjects using the product of example 6 for a period of 21 days. The summary of the observations by the examining doctors was carried out on the day of the inclusion visit V1D0 then after regular application at the final visit V2D21. 8.1 Selection of the study subjects The sample analyzed represents 30 adult subjects, of which 53% were female and 47% were male, presenting mild to moderate psoriasis. The age of these subjects was between 21 years and 62 years and represented an average of 43 years. 8.2 Conducting the study The test took place over a period of 21 days. It comprised 2 medical visits: one planned before starting the treatment (V1D0) and the other after 21 days of regular applications of the product (V2D21). A telephone interview (E1H24) was carried out 24 hours after the inclusion visit (V1D0). For each subject included in the study, the product had to be used as often as necessary, in case of itching over the zone(s) concerned for 21 days. On average, the product was applied 2.5 times per day. 10 . . . . . . . . . . . . . . . . . . . . . During the visits, the subjects were examined in order to determine their score via the 5- D pruritus questionnaire. The individual scores of each item (duration, degree and direction) correspond to the value that was associated with them in the questionnaire (going from 1 to 5). The areas of disability include 4 items evaluating the impact of itching on daily activities (sleep, social activities, household tasks, work). The disability score is calculated by taking the highest score of one of these 4 items. The number of parts of the body affected by itching is taken into account and the sum defines a score given: • Between 0 and 2: score of 1 • Between 3 and 5: score of 2 • Between 6 and 10: score of 3 • Between 11 and 13: score of 4 • Between 14 and 16: score of 5 The final score corresponds to the sum of the scores previously obtained: • The duration • The degree • The direction • The disablement • The distribution Further, at each visit, a clinical examination was carried out in order to analyze the state of the skin of the subjects, according to 6 clinical items and a 10-level rating scale detailed in the table below. [Image disponible dans le document PDF, Image available in the PDF document] Furthermore, the evaluation of the personal context was carried out at V1D0 and at V2D21 according to 14 items and a 10-level rating scale detailed in the table below. 4. [Image disponible dans le document PDF, Image available in the PDF document] In addition, the SKINDEX questionnaire was used to evaluate the quality of life of the subjects, according to a 5-level rating scale from 0: never to 4: all the time, detailed in the table below. [Image disponible dans le document PDF, Image available in the PDF document] The results of the SKINDEX are reported by three scores each representing a given dimension of the quality of life: • Emotion • Symptoms ٠ Functioning. The questions relating to the Emotion score are numbered: 3, 6, 9, 12, 13, 15, 21, 23, 26, 28. The questions relating to the Symptoms score are numbered: 1, 7, 10, 16, 19, 24, 27. The questions relating to the Functioning score are numbered: 2, 4, 5, 8, 11, 14, 17, 20, 22, 25, 29, 30. Question 18 is not included in the calculation of the scores. The score of each dimension is the average of the responses to each question on this dimension. The scores are converted into a percentage. The higher the score, the greater the impact in terms of quality of life. Further, the users self-evaluated the product according to several criteria. A first self-evaluation by the subject was gathered 24 hours after the first use of the product for 7 items according to a 5-level rating scale: 11 i . . [Image disponible dans le document PDF, Image available in the PDF document] The perceived efficacy was analyzed according to the levels of perceptions, collected and interpreted as follows: 5 • Ratings 3 and 4 (Often, All the time): "Favorable" perceptions, • Rating 2 (From time to time): "Moderate" perceptions, • Ratings 0 and 1 (Never, Rarely): "Unfavorable" perceptions. The overall analysis of the efficacy was also evaluated at the final visit at V2D21, by the 10 user according to a 5-level rating scale (Completely agree, Agree, Disagree, Completely disagree, No opinion). The Favorable perceptions correspond to ratings 1 and 2 (Completely agree, Agree) and the Unfavorable perceptions correspond to ratings 3 and 4 (Disagree, Completely disagree). 8.3.1 Evaluation of the subject via the 5-D pruritus questionnaire The results of the evaluation of the subject via the 5-D pruritus questionnaire are shown 20 in the table below and illustrated in Figure 8. [Image disponible dans le document PDF, Image available in the PDF document] • . . [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 8.3.2 Clinical evaluation of the subject The results of the clinical evaluation of the subject are shown in the table below and illustrated in Figure 9. [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 8.3.3 Evaluation of the individual context of the subject The results of the evaluation of the individual context of the subject are shown in the table below. 1 1 . . . . . . . . . . . . . . . . . . . . . [Image disponible dans le document PDF, Image available in the PDF document] . The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- 5 significant; S: p<0.05; S*: p<0.01; NA: Not Available. 11 1. <semantics>(x,y)=(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y)⋅(x,y<annotation encoding="application / x-tex">(x,y) = (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y) \cdot (x,y< / annotation>< / semantics> 8.3.4 Analysis of the quality of life of users The results of the evaluation of the quality of life of users are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 10 8.3.5 Analysis of the self-evaluation of users The results of the perception of efficacy at 24 hours are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] 15 The results of the perception of efficacy at D21 are shown in the table below. 1. . . . . . . . . . . . . . . . . . . . . 4 · · · · · · · · · · · · · · · · · · · [Image disponible dans le document PDF, Image available in the PDF document] 8.4 Conclusions The results obtained after regular applications show an improvement of the skin state: namely a decrease in the average ratings for sensations of itching (-48%), roughness of the skin and flaking (-43%), skin dryness (-41%), skin lesions (-29%) and an improvement in skin suppleness (+25%). The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with, for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. The 30 subjects included with mild to moderate psoriasis, without outbreak, presented pruritus of which the evolution was analyzed from the 5D-pruritus evaluation scale. After repeated applications of the product, the overall score of the 5D-pruritus is improved (-35%) after 21 days of repeated applications with a significant difference (p<0.01) in favor of the product of the invention. The quality of life of the subjects was also analyzed before and after 21 days of repeated applications according to the SKINDEX questionnaire. The results obtained show an improvement in the quality of life of the subjects in the 3 dimensions of the SKINDEX: symptoms (-44%), functioning (-36%), and emotions (-33%). The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with, for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. A self-evaluation of the product of the invention was carried out by the users after 24 hours in order to judge the immediate efficacy of the product. 94% of users considered that the product reduces the urge to scratch from the first application. For 93% of subjects, the product soothes, relieves the skin from the first application. 90% of users considered that from the first application the product moisturizes the skin, decreases skin dryness, leaves the skin more supple and softer from the first application. For 80% of users, the product leaves the skin more supple from the first application. After 21 days of repeated applications, the efficacy according to users was evaluated for 18 items. The results obtained show that 100% of users felt that the product calms the sensations of irritation, has a soothing action on the skin, decreases the urge to scratch and leaves a protective film on the skin. All users felt that the product immediately soothes, relieves itching, decreases skin irritation, gives a sensation of immediate comfort, moisturizes the skin, lastingly decreases the sensation of itching, reduces redness linked to scratching, gives a long- lasting sensation of comfort and makes the skin softer. The product decreases skin dryness for 100% of users and nourishes the skin for 97% of users. t. Example 9 / Clinical study on the efficacy of the composition of the invention in the treatment of chronic urticaria The effect of the composition of the invention in the treatment of chronic urticaria was tested during the clinical trial described below. The product corresponding to the formulation of example 6 was clinically tested in adult subjects presenting chronic urticaria. This involved the subjects using the product of example 6 for a period of 21 days. The summary of the observations by the examining doctors was carried out on the day of the inclusion visit V1D0 then after regular application at the final visit V2D21. 9.1 Selection of the study subjects The sample analyzed represents 30 adult subjects, of which 60% were female and 40% were male, presenting chronic urticaria. The age of these subjects was between 18 years and 82 years and represented an average of 45 years. 9.2 Conducting the study The test took place over a period of 21 days. It comprised 2 medical visits; one planned before starting the treatment (V1D0) and the other after 21 days of regular applications of the product (V2D21). A telephone interview (E1H24) was carried out 24 hours after the inclusion visit (V1D0). For each subject included in the study, the product had to be used as often as necessary, in case of itching over the zone(s) concerned for 21 days. On average, the product was applied 2.3 times per day. During the visits, the subjects were examined in order to determine their score via the 5- D pruritus questionnaire (identical criteria to those detailed in point 8.2). Further, at each visit, a clinical examination was carried out in order to analyze the state of the skin of the subjects, according to 6 clinical items and a 10-level rating scale identical to those detailed in point 8.2. Furthermore, the evaluation of the personal context was carried out at V1D0 and at V2D21 according to 14 items and a 10-level rating scale detailed in point 8.2. Furthermore, the 11 į. SKINDEX questionnaire was used to evaluate the quality of life of the subjects, according to a rating scale detailed in point 8.2. In addition, users self-evaluated the product according to the criteria detailed in point 8.2. 5 9.3 Results of the study 9.3.1 Evaluation of the subject via the 5-D pruritus questionnaire. The results of the evaluation of the subject via the 5-D pruritus questionnaire are shown 10 in the table below and illustrated in Figure 10. [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- 15 significant; S: p<0.05; S*: p<0.01; NA: Not Available. 9.3.2 Clinical evaluation of the subject The results of the clinical evaluation of the subject are shown in the table below and 20 illustrated in Figure 11. 11 1 [Image disponible dans le document PDF, Image available in the PDF document] • The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 9.3.3 Evaluation of the individual context of the subject The results of the evaluation of the individual context of the subject are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] . . - 1 [Image disponible dans le document PDF, Image available in the PDF document] . The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 5 9.3.4 Analysis of the quality of life of users The results of the evaluation of the quality of life of users are shown in the table below. × [Image disponible dans le document PDF, Image available in the PDF document] . i 4.5 . The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 5 9.3.5 Analysis of the self-evaluation of users The results of the perception of efficacy at 24 hours are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] . 10 The results of the perception of efficacy at D21 are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] : . . [Image disponible dans le document PDF, Image available in the PDF document] * 9.4 Conclusions The results obtained after regular applications show an improvement of the skin state: namely a decrease in the average ratings for sensations of itching (-58%), size of skin lesions (-54%), flaking (-48%), skin dryness (-40%), roughness of the skin to touch (-36%) and an improvement in skin suppleness (+16%). The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with, for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. The 30 subjects included with chronic urticaria presented pruritus, of which the evolution was analyzed from the 5D-pruritus evaluation scale. After repeated applications of the product, the overall score of the 5D-pruritus is improved (-35%) after 21 days of repeated applications with a significant difference (<semantics>p<0.01<annotation encoding="application / x-tex">p<0.01< / annotation>< / semantics>) in favor of the product of the invention. The quality of life of the subjects was also analyzed before and after 21 days of repeated applications according to the SKINDEX questionnaire. The results obtained show an improvement in the quality of life of the subjects in the 3 dimensions of the SKINDEX: functioning (-52%), symptoms (-48%), and emotions (-45%). 1 1 The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with, for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. A self-evaluation of the product of the invention was carried out by the users after 24 hours in order to judge the immediate efficacy of the product. For 87% of the subjects, the product relieves, soothes the skin from the first application and leaves a protective film on the skin from the first application. 86% of subjects felt that from the first application the product soothes / relieves the skin and moisturizes the skin. The product leaves the skin softer from the first application for 83% of subjects. 80% found that the product leaves the skin more supple from the first application and 77% of users claimed that the product reduces skin dryness from the first application. After 21 days of repeated applications, the efficacy according to users was evaluated for 18 items. The results obtained show that 100% of users feel that the product calms the sensations of irritation and has a soothing action on the skin. For 97% of subjects, the product reduces the urge to scratch and leaves a protective film on the skin. For 93% of subjects, the product immediately relieves and soothes itching, decreases skin irritation and gives a sensation of immediate comfort. 90% of users claimed that the product moisturizes the skin. 83% felt that the product lastingly reduces the sensation of itching. 80% found that the product reduces redness linked to scratching, gives a sensation of long-lasting comfort and makes the skin softer. The product reduces skin dryness from for 77% of users. However, two items gave a relatively high "No opinion" rating, which corresponds to little relevance of the evaluated effects. Thus, 30% of users had no opinion on the fact that the product nourishes the skin and 20% did not express an opinion on the ability of the product to make the skin more supple. Example 10 / Clinical study of the efficacy of the composition of the invention in the treatment of senile pruritus The effect of the composition of the invention in the treatment of senile pruritus was tested during the clinical trial described below. The product corresponding to the formulation of example 6 was clinically tested in adult subjects presenting senile pruritus. This involved Ţi the subjects using the product of example 6 for a period of 21 days. The summary of the observations by the examining doctors was carried out on the day of the inclusion visit V1D0 then after regular application at the final visit V2D21. 10.1 Selection of the study subjects The sample analyzed represents 30 adult subjects, of which 60% were female and 40% were male, presenting mild to moderate senile pruritus. The age of these subjects was between 66 years and 89 years and represented an average of 72 years. 10.2 Conducting the study The test took place over a period of 21 days. It comprised 2 medical visits; one planned before starting the treatment (V1D0) and the other after 21 days of regular applications of the product (V2D21). A telephone interview (E1H24) was carried out 24 hours after the inclusion visit (V1D0). For each subject included in the study, the product had to be used as often as necessary, in case of itching over the zone(s) concerned for 21 days. On average, the product was applied 2.9 times per day. During the visits, the subjects were examined in order to determine their score via the 5- D pruritus questionnaire (identical criteria to those detailed in point 8.2). Further, at each visit, a clinical examination was carried out in order to analyze the state of the skin of the subjects, according to 6 clinical items and a 10-level rating scale identical to those detailed in point 8.2. Furthermore, the evaluation of the personal context was carried out at V1D0 and at V2D21 according to 14 items and a 10-level rating scale detailed in point 8.2. Furthermore, the SKINDEX questionnaire was used to evaluate the quality of life of the subjects, according to a rating scale detailed in point 8.2. In addition, users self-evaluated the product according to the criteria detailed in point 8.2. Į I - 1 . 10.3 Results of the study 10.3.1 Evaluation of the subject via the 5-D pruritus questionnaire 5 The results of the evaluation of the subject via the 5-D pruritus questionnaire are shown in the table below and illustrated in Figure 12. [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 10.3.2 Clinical evaluation of the subject 15 The results of the clinical evaluation of the subject are shown in the table below and illustrated in Figure 13. . . . • • [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- 5 significant; S: p<0.05; S*: p<0.01; NA: Not Available. 10.3.3 Evaluation of the individual context of the subject The results of the evaluation of the individual context of the subject are shown in the 10 table below. . [Image disponible dans le document PDF, Image available in the PDF document] . t i . . . [Image disponible dans le document PDF, Image available in the PDF document] The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 5 10.3.4 Analysis of the quality of life of users The results of the evaluation of the quality of life of users are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] . i i . . . . . The statistical significance, established on the comparison of ranks, is mentioned for information with the results of the descriptive analysis. *Statistical significance: NS: non- significant; S: p<0.05; S*: p<0.01; NA: Not Available. 5 10.3.5 Analysis of the self-evaluation of users The results of the perception of efficacy at 24 hours are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] 10 The results of the perception of efficacy at D21 are shown in the table below. [Image disponible dans le document PDF, Image available in the PDF document] . · i . į į 55 [Image disponible dans le document PDF, Image available in the PDF document] 10.4 Conclusions The results obtained after regular applications show an improvement of the skin state: namely a decrease in the average ratings for sensation of itching (-56%), skin flaking (-52%), roughness of the skin to touch and the size of cutaneous lesions (-44%), skin dryness (-41%) and an improvement in skin suppleness (+35%). The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. The 30 subjects included with mild to moderate senile pruritus, presented pruritus of which the evolution was analyzed from the 5D-pruritus evaluation scale. After repeated applications of the product, the overall score of the 5D-pruritus is improved (-37%) after 21 days of repeated applications with a significant difference (p<0.01) in favor of the product of the invention. The quality of life of the subjects was also analyzed before and after 21 days of repeated applications according to the SKINDEX questionnaire. The results obtained show an improvement in the quality of life of the subjects in the 3 dimensions of the SKINDEX: functioning (-75%), emotions (-66%), and symptoms (-57%). The statistical comparisons of the data obtained at D21 relative to D0 confirm these performances with, for each of the evaluated criteria, a significant difference (p<0.01) in favor of the product of the invention. A self-evaluation of the product of the invention was carried out by the users after 24 hours in order to judge the immediate efficacy of the product. 97% of users considered that the product reduces the urge to scratch from the first application. For 96% of subjects, the product decreases skin dryness from the first application. 93% of subjects felt that from the first application the product moisturizes the skin, and leaves it more supple. For 90% of users, the product leaves a protective film on the skin from the first application. Only 50% of users felt that the product leaves the skin more supple from the first application. After 21 days of repeated applications, the efficacy according to users was evaluated for 18 items. The results obtained show that 100% of users felt that the product calms the sensations of irritation, has a soothing action on the skin, decreases the urge to scratch and leaves a protective film on the skin. All users felt that the product immediately relieves and soothes itching, decreases skin irritation, gives a sensation of immediate comfort, and moisturizes the skin. For 97% of users, the product reduces redness linked to scratching. The product nourishes the skin and lastingly decreases the sensations of itching for 93% of users. However, the item "the product makes the skin more supple" had a relatively high level of "No opinion" (23%), which corresponds to little relevance of the evaluated effect. REFERENCES Bonini et al. (1996) Circulating nerve growth factor levels are increased in humans with allergic disease and asthma Proc. Natl. Acad. Sci USA 93: 10955-10960. Farquhar-Smith W.P. et al. (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain, 97(1-2):11-21. Hägermark et al. (1978) Flare and itch induced by substance P in human skin. J Invest Dermatol. Oct;71(4):233-5. 11 Jacquier C. (2008) Prise en charge du prurit en médecine générale. Thesis for Doctor of Medicine, University Henri Poincaré Nancy-I, 2008 Kim N.H. et al. (2010) Nicotinamide in dermatology. Expert Review of Dermatology. 5 5(1): 23-29. Lee Y.M. et al. (2012) The role of TRPV1 channel in aged human skin. J Dermatol Sci. 65(2):81-85. Misery L. (2014) Pruritus: considerable progress in pathophysiology, Med. Sci. (Paris): 30(12):1123-1128. Nakamura A. et al. (1999) Recent advances in neuropharmacology of cutaneous nociceptors". Jpn J Pharmacol. 79(4):427-31. Raychaudhuri S.P. et al. (2004). Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis Prog Brain Res. 146:433–437. Soma Y. et al. (2005) Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 44(3):197-202. 200 Szepietowski, C et al. (2002) Itching in patients suffering from psoriasis, Acta Dermat. Croat., 10(4): 221-226. Tanno O. et al (2000) Niacinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the permeability barrier. Br J Dermatol, 143(3): 524-531. Truzzi F. et al. (2011) Neurotrophins in healthy and diseased skin. Dermatoendocrinol. 3(1):32-6. doi: 10.4161 / derm.3.1.14661. Tominaga M. et al. (2014) Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. Mar;41(3):205-12. doi: 10.1111 / 1346-8138.12317. i . Wisnicka B. et al. (2004) Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis. Dermat. and Psychosom. 5(2): 73–78. . . ů. . * . •

Claims

<pat:ClaimStatement>CLAIMS< / pat:ClaimStatement> <pat:Claims com:id="claims"> <pat:Claim com:id="CLM-00001"> <pat:ClaimNumber>1< / pat:ClaimNumber> <pat:ClaimText>1. Use of a cosmetic composition comprising an ambora extract and a green tea extract, wherein the ambora extract represents between 0.00005% and 1% by weight of the composition, for treatment of a dermatological disorder causing pruritus, antihistamine- resistant pruritus, or senile pruritus in a patient in need thereof. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00002"> <pat:ClaimNumber>2< / pat:ClaimNumber> <pat:ClaimText>2. The use according to claim 1, wherein the green tea extract is rich in epigallocatechin 3-O-gallate. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00003"> <pat:ClaimNumber>3< / pat:ClaimNumber> <pat:ClaimText>3. The use according to claim 1 or 2, wherein the green tea extract represents between < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00004"> <pat:ClaimNumber>4< / pat:ClaimNumber> <pat:ClaimText>4. The use according to claim 3, wherein the green tea extract represents between 0.001% and 0.1% by weight of the composition. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00005"> <pat:ClaimNumber>5< / pat:ClaimNumber> <pat:ClaimText>5. The use according to any one of claims 1 to 4, wherein the composition further comprises <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>-glycyrrhetinic acid. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00006"> <pat:ClaimNumber>6< / pat:ClaimNumber> <pat:ClaimText>6. The use according to claim 5, wherein the <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>-glycyrrhetinic acid represents between < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00007"> <pat:ClaimNumber>7< / pat:ClaimNumber> <pat:ClaimText>7. The use according to claim 6, wherein the <semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>-glycyrrhetinic acid represents between < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00008"> <pat:ClaimNumber>8< / pat:ClaimNumber> <pat:ClaimText>8. The use according to any one of claims 1 to 4, wherein the composition further comprises N-palmitoyl-ethanolamide. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00009"> <pat:ClaimNumber>9< / pat:ClaimNumber> <pat:ClaimText>9. The use according to claim 8, wherein the N-palmitoyl-ethanolamide represents between 0.1% and 1% by weight of the composition. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00010"> <pat:ClaimNumber>10< / pat:ClaimNumber> <pat:ClaimText>10. The use according to any one of claims 1 to 9, wherein the composition further comprises vitamin B3 and / or a derivative thereof, wherein the derivative is tocopheryl nicotinate or methyl nicotinate. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00011"> <pat:ClaimNumber>11< / pat:ClaimNumber> <pat:ClaimText>11. The use according to claim 10, wherein the vitamin B3 and / or the derivative thereof represents between 0.001% and 2% by weight of the composition. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00012"> <pat:ClaimNumber>12< / pat:ClaimNumber> <pat:ClaimText>12. The use according to any one of claims 1 to 11, wherein the composition is sprayable. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00013"> <pat:ClaimNumber>13< / pat:ClaimNumber> <pat:ClaimText>13. The use according to any one of claims 1 to 12, wherein the dermatological disorder causing pruritus is psoriasis, atopic dermatitis, or chronic urticaria. < / pat:ClaimText> < / pat:Claim> < / pat:Claims>